- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Barcelona clinic liver cancer (BCLC) Hepatocellular carcinoma (HCC)
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Durvalumab Tremelimumab – May 2025
Durvalumab and Tremelimumab: Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi®; Tremelimumab: Solution concentrate for I.V. infusion 300 mg in 15 mL; Imjudo®
Last updated
9 May 2025